These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37796134)

  • 1. Nanotechnology-Based Strategies for Extended-Release Delivery of Angiotensin Receptor Blockers (ARBs): A Comprehensive Review.
    Haji Ali B; Shirvaliloo M; Fathi-Karkan S; Mirinejad S; Ulucan-Karnak F; Sargazi S; Sargazi S; Sheervalilou R; Rahman MM
    Chem Biodivers; 2023 Nov; 20(11):e202301157. PubMed ID: 37796134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
    Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
    Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of irbesartan in the management of hypertension.
    Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
    Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The place of ARBs in heart failure therapy: is aldosterone suppression the key?
    Markan U; Pasupuleti S; Pollard CM; Perez A; Aukszi B; Lymperopoulos A
    Ther Adv Cardiovasc Dis; 2019; 13():1753944719868134. PubMed ID: 31401939
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pleiotropic effects of angiotensin receptor blockers.
    Chrysant SG; Chrysant GS
    J Clin Hypertens (Greenwich); 2006 Apr; 8(4):261-8. PubMed ID: 16596029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
    Michel MC; Foster C; Brunner HR; Liu L
    Pharmacol Rev; 2013 Apr; 65(2):809-48. PubMed ID: 23487168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telmisartan is the most effective ARB to increase adiponectin via PPARα in adipocytes.
    Hattori N; Yamada A; Nakatsuji S; Matsuda T; Nishiyama N; Shimatsu A
    J Mol Endocrinol; 2022 May; 69(1):259-268. PubMed ID: 35354667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II type 1 receptor blockers decrease kynurenic acid production in rat kidney in vitro.
    Zakrocka I; Targowska-Duda KM; Wnorowski A; Kocki T; Jóźwiak K; Turski WA
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Feb; 392(2):209-217. PubMed ID: 30370429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults.
    Dorosch T; Ganzer CA; Lin M; Seifan A
    Curr Pain Headache Rep; 2019 Sep; 23(11):85. PubMed ID: 31515634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential pharmacology and benefit/risk of azilsartan compared to other sartans.
    Kurtz TW; Kajiya T
    Vasc Health Risk Manag; 2012; 8():133-43. PubMed ID: 22399858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan.
    Omboni S; Volpe M
    Adv Ther; 2019 Feb; 36(2):278-297. PubMed ID: 30591990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
    Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY
    Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin Receptor Blockers Effect on Serum Uric Acid-A Class Effect?
    Sutton Burke EM; Kelly TC; Shoales LA; Nagel AK
    J Pharm Pract; 2020 Dec; 33(6):874-881. PubMed ID: 31390929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.
    Belsey JD
    J Med Econ; 2011; 14(5):553-61. PubMed ID: 21707445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.
    Al Khalaf MM; Thalib L; Doi SA
    Am J Cardiovasc Drugs; 2009; 9(1):29-43. PubMed ID: 19178130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
    ARB Trialists Collaboration
    J Hypertens; 2011 Apr; 29(4):623-35. PubMed ID: 21358417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.